Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Acadia Pharmaceuticals Inc.
  • Alcobra Ltd.
  • Arena Pharmaceuticals Inc.
  • Argos Therapeutics Inc.
  • Avanir Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals Inc.
  • BioDelivery Sciences International Inc.
  • Cara Therapeutics Inc.
  • Catalyst Pharmaceutical Partners Inc.
  • Clovis Oncology Inc.
  • Conatus Pharmaceuticals
  • Geron Corp.
  • Inovio Pharmaceuticals Inc.
  • Mirati Therapeutics
  • Neurocrine Biosciences
  • Orexigen Therapeutics Inc.
  • Peregrine Pharmaceuticals Inc.
  • Roche Holding AG
  • Sangamo BioSciences Inc.
  • Thoratec Corp.
  • Threshold Pharmaceuticals Inc.
  • Vivus Inc.

Charles Duncan

Piper Jaffray & Co.

Image: Charles Duncan

Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.




Recent Interviews

Piper Jaffray's Charles Duncan Addresses Pot Shots (6/26/14) Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock.

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers (4/24/14) Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and Duncan believes now is the time to identify, through careful diligence, companies that can advance in a more temperate market. In this interview with The Life Sciences Report, Duncan discusses five biotech and specialty pharma innovators poised to produce therapies enabled by versatile and scalable technology platforms that target multiple disease indications.

Recent Quotes

"INO is moving its Ebola DNA vaccine into Phase 1 trials with GeneOne." (9/25/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"We reiterate our Overweight rating on THLD." (9/22/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"INO's $109M in cash at Q2/14E should fund operations through 2017." (8/11/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"THLD's Phase 3 TH-302 safety/efficacy data are expected in September." (8/1/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"INO's first controlled test of its platform met the primary endpoint." (7/23/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"BDSI's second Phase 3 buprenorphine study met its primary endpoint." (7/7/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"BDSI's Phase 3 data for BBCP are expected in the next few weeks." (6/27/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >

more comments

"INO's near-term catalyst is its ongoing Phase 2 in cervical dysplasia." (6/24/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"Results from INO's Phase 2, VGX-3100 in CD study is a key data point." (6/17/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"The FDA approved BDSI's Bunavail for treating opioid dependence." (6/8/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"THLD's TH-302 programs in multiple myeloma and glioblastoma multiforme are becoming increasingly visible." (6/3/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"The dismissed suit is a clear positive for BDSI." (5/22/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"CPRX will likely be first to market with orphan designation in LEMS." (5/22/14) Catalyst Pharmaceutical Partners Inc. - Charles Duncan, Piper Jaffray & Co. More >

"BDSI has a strong cash position and numerous upcoming catalysts." (5/12/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"INO's Phase 2a data would provide key validation of the platform." (5/12/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"We model THLD as fully funded through at least 2015." (5/2/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"THLD's soft-tissue sarcoma study should read out at the end of 2015; that could be a very exciting time." (4/24/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >

"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform." (4/24/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report interview with Charles Duncan More >

"By the end of 2014, you're going to have some pretty good news flow out of BDSI." (4/24/14) BioDelivery Sciences International Inc. - The Life Sciences Report interview with Charles Duncan More >

"BDSI's robust presence at ASAM should raise awareness of Bunavail." (4/7/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"We are increasing our price target for BDSI and we reiterating our Overweight rating." (10/4/13) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"INO's partnership with Roche provides further validation of its platform electroporation/SynCon technologies." (9/10/13) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

fewer comments


Due to permission requirements, not all quotes are shown.